RJA
ACAD icon

Raymond James & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Raymond James & Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-11,000
Closed -$17K – 3240
2016
Q3 		$17K Hold
11,000
– – ﹤0.01% 3143
2016
Q2 		$41K Buy
+11,000
New +$368K ﹤0.01% 2887

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Raymond James & Associates's ACAD Position: Q3 2024 in Review

Raymond James & Associates reduced its Acadia Pharmaceuticals (ACAD) stake by 2.3% in Q3 2024, selling an estimated $5.55K and leaving 14,119 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #3595.

Raymond James & Associates first reported a position in ACAD in Q4 2014 and has held it in 20 quarters since. The position peaked at $2.12M in Q4 2015. 257 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Raymond James & Associates held 14,119 shares of Acadia Pharmaceuticals worth $217K as of Q3 2024.
  • Raymond James & Associates sold 333 Acadia Pharmaceuticals shares in Q3 2024, an estimated $5.55K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3595 holding.
  • Raymond James & Associates first reported a position in Acadia Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Raymond James & Associates's Acadia Pharmaceuticals position peaked at $2.12M in Q4 2015.
  • 257 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.